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Background
The current treatment of choice for Normal Pressure
Hydrocephalus (NPH) is a CSF shunt, however, this car-
ries significant morbidity with reported complication
rates following shunt surgery averaging 38%, with a 6%
rate of permanent neurological deficit or death [1]. NPH
can be viewed as a slowly progressive communicating
hydrocephalus. Endoscopic coagulation of the choroid
plexus (CPC) has been shown to be an effective treatment
of communicating hydrocephalus in children, particularly
when it is slowly progressing. It has not yet been evaluated
in adults with NPH. Endoscopic third ventriculostomy
(ETV) has been shown to be effective in selected cases of
NPH. Published results of both endoscopic techniques
suggest that complication rates are lower than for CSF
shunt surgery. A combination of endoscopic CPC and ETV
may provide an attractive alternative to CSF shunting with
equivalent rates of responsiveness and lower surgical mor-
bidity. The aim of this study is to evaluate the effectiveness
of endoscopic treatment of NPH compared to CSF shunt-
ing.
Study Design
An equivalence study, with the null hypothesis that there
is no significant difference in outcome between treatment
with CSF shunting and treatment with endoscopy 3
months after treatment. Consenting patients with a diag-
nosis of NPH, satisfying the trial inclusion and exclusion
criteria, are randomised to either endoscopic surgery or
CSF shunt (control) treatment. The primary outcome
measure is the Gait Score [2] at 3 months post-operatively.
Secondary outcome measures are: operative mortality, fre-
quency of operative complications, Mattis dementia rat-
ing score II, NPH Score, Grooved Pegboard Test score,
Quality of life (SF36), modified Rankin score, Barthel
index. Outcome assessment is blinded.
Statistical Evaluation
With a sample size of 32 patients in each group, a two
group 5% one sided t-test will have 90% power to detect
an effect size of 0.75. Sequential monitoring of major
morbidity and mortality rates will be undertaken and the
trial terminated if these rates exceed a predetermined
threshold.
Conclusions
This study aims to evaluate the efficacy and safety of endo-
scopic CPC with ETV in the treatment of NPH. An interim
analysis of results will be presented.
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